Antibody pairs, reagents, and methods for detecting influenza A virus

By providing antibody pairs with specific sequences for sandwich method detection of influenza A virus, the problems of insufficient detection timeliness and accuracy in existing technologies are solved, and rapid and sensitive virus detection is achieved.

CN119591697BActive Publication Date: 2026-11-10DONGGUAN PENGZHI BIOTECH CO LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202311149709.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-09-06
Publication Date
2026-11-10
Estimated Expiration
2043-09-06

AI Technical Summary

Technical Problem

Current technologies are insufficient for the rapid and accurate detection of influenza A virus, resulting in a lack of timeliness and accuracy in clinical treatment plans.

Method used

An antibody pair is provided, comprising complementary determinant regions of heavy and light chains with specific sequences, for sandwich detection of influenza A virus, which binds to antigens to form immune complexes and indicates the presence of the virus via markers.

Benefits of technology

It enables rapid and sensitive detection of influenza A virus, improving the accuracy and timeliness of diagnosis and meeting clinical needs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

This invention discloses antibody pairs, reagents, and methods for detecting influenza A virus, relating to the field of immunodiagnostics. The antibody pairs for detecting influenza A virus disclosed in this invention include a first antibody and a second antibody. Reagents and detection methods based on this antibody combination can accurately detect the presence of influenza A virus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of immunodiagnostic technology, and more specifically, to an antibody pair, reagent, and method for detecting influenza A virus. Background Technology

[0002] Influenza is an acute respiratory infectious disease that humanity has not yet fully conquered. It has the highest incidence rate among all infectious diseases and is one of the major public health problems facing humankind. It was the first infectious disease to be monitored globally. Influenza viruses belong to the Orthomyxoviridae family and are enveloped, segmented, single-stranded, negative-sense RNA viruses, appearing as spherical or filamentous forms. Based on the antigenicity of their internal nucleoprotein (NP) and matrix protein (M), they can be divided into three types: A, B, and C. Based on the antigenicity of the viral particle outer membrane hemagglutinin (HA) and neuraminidase (NA) proteins, type A influenza viruses are currently classified into 16 H subtypes (H1-H16) and 9 N subtypes (N1-N9). Among type A influenza viruses, there have been reports of human infections with subtypes H1, H2, H3, H5, H7, and H9. Because the nucleotide sequences encoding HA and / or NA are prone to mutation, the antigenic epitopes of HA and / or NA are altered. This antigenic shift renders the original specific immunity of the population ineffective, so influenza A viruses often cause large-scale or even worldwide influenza epidemics.

[0003] Over the past few decades, seasonal influenza viruses have primarily been concentrated in the A-type H3N2 and H1N1 subtypes. In recent years, outbreaks of novel A-type influenza virus subtypes have occurred frequently. For example, the 2009 novel A-type H1N1 influenza virus caused a global influenza pandemic, and cases of human infection with highly pathogenic avian influenza (H5 subtype) viruses have been frequently reported. The avian A-type H5N1 subtype influenza virus is considered to have the potential to cause widespread human influenza epidemics. Novel A-type influenza viruses are usually caused by segmental recombination of genes. This extensive genetic alteration can lead to significant changes in viral antigenic properties, a phenomenon known as antigenic shift. The novel A-type H1N1 influenza virus (2009) simultaneously contained gene segments from avian influenza, swine influenza, and human seasonal influenza, resulting in significant changes at the antigenic level. Due to these significant antigenic changes and the potential for increased viral virulence, the infectivity and severity of the virus have increased, thus the novel A-type influenza virus may cause higher morbidity and mortality. Because the clinical manifestations of influenza lack specificity, it is difficult to differentiate from acute respiratory infections caused by other pathogens. Furthermore, the clinical reporting time for traditional etiological testing methods is relatively slow, resulting in clinicians often resorting to empirical, trial-and-error treatments based on the patient's condition. Therefore, there is an urgent clinical need for a highly timely diagnostic reagent that can rapidly confirm the diagnosis of influenza A virus.

[0004] Immunological detection methods are considered ideal for detecting influenza A virus, offering advantages such as ease of detection, rapid results, and high sensitivity. Through long-term research, the inventors discovered that the sandwich pairing of influenza A virus antibody raw materials is, besides the antibody raw materials themselves, the key to achieving immunodetection of influenza A virus. Summary of the Invention

[0005] This application provides an antibody pair that offers an important source of paired antibody raw materials for the detection of influenza A virus and has good detection performance.

[0006] To achieve the above objectives, according to one aspect of the present invention, an antibody pair for detecting influenza A virus is provided. The antibody pair includes a first antibody comprising: three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3) in the heavy chain variable region shown in SEQ ID NO:9, and three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3) in the light chain variable region shown in SEQ ID NO:11;

[0007] The antibody pair includes a second antibody, which comprises: three heavy chain complementarity-determining regions, HCDR1, HCDR2 and HCDR3, in the heavy chain variable region shown in SEQ ID NO:20, and three light chain complementarity-determining regions, LCDR1, LCDR2 and LCDR3, in the light chain variable region shown in SEQ ID NO:22.

[0008] The complementary decision region is defined by any one or a combination of systems such as Kabat, Chothia, IMGT, AbM, or Contact.

[0009] To achieve the above objective, according to a second aspect of the present invention, an antibody pair for detecting influenza A virus is provided, the antibody pair comprising a first antibody having HCDR1 shown in SEQ ID NO:1, HCDR2 shown in SEQ ID NO:2, HCDR3 shown in SEQ ID NO:3, LCDR1 shown in SEQ ID NO:4, LCDR2 shown in SEQ ID NO:5, and LCDR3 shown in SEQ ID NO:6.

[0010] The antibody pair includes a second antibody having HCDR1 as shown in SEQ ID NO:13 and HCDR1 as shown in SEQ ID NO:14.

[0011] HCDR2, HCDR3 (SEQ ID NO:15), LCDR1 (SEQ ID NO:16), and LCDR2 (SEQ ID NO:17)

[0012] LCDR3 as shown in SEQ ID NO:18.

[0013] To achieve the above objectives, according to a third aspect of the present invention, an antibody pair for detecting influenza A virus is provided;

[0014] The antibody pair comprises a first antibody, which comprises at least one of (1)-(2):

[0015] (1) The heavy chain variable region shown in SEQ ID NO:9 and the light chain variable region shown in SEQ ID NO:11;

[0016] (2) The heavy chain shown in SEQ ID NO:10 and the light chain shown in SEQ ID NO:12;

[0017] The antibody pair comprises a second antibody, the second antibody comprising at least one of (a)-(b):

[0018] (a) The heavy chain variable region shown in SEQ ID NO:20 and the light chain variable region shown in SEQ ID NO:22;

[0019] (b) The heavy chain shown in SEQ ID NO:21 and the light chain shown in SEQ ID NO:23.

[0020] To achieve the above objectives, according to a fourth aspect of the present invention, an antibody pair for detecting influenza A virus is provided;

[0021] The antibody pair comprises a first antibody, wherein the variable region of the heavy chain of the first antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:9, and the variable region of the light chain of the first antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:11; or;

[0022] The antibody pair comprises a second antibody, wherein the variable region of the heavy chain of the second antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:20, and the variable region of the light chain of the second antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:22.

[0023] In one alternative implementation, the mutation is the addition, deletion, substitution, or modification of one or more amino acids in the framework region of the first or second antibody.

[0024] In one alternative implementation, the framework region of the conserved variant formed by the mutation of the first antibody has at least 80% identity with the framework region of the first antibody before the mutation; or;

[0025] The framework region of the conserved variant formed by the mutation of the second antibody has at least 80% identity with the framework region of the second antibody before the mutation.

[0026] To achieve the above objectives, according to a fifth aspect of the present invention, an antibody pair for detecting influenza A virus is provided;

[0027] The antibody pair comprises a first antibody that binds to an epitope, the epitope being the same as the epitope bound by the antibody comprising the heavy chain variable region shown in SEQ ID NO:9 and the light chain variable region shown in SEQ ID NO:11.

[0028] The antibody pair comprises a second antibody that binds to an epitope: the epitope is the same as the epitope bound to the antibody comprising the heavy chain variable region shown in SEQ ID NO:20 and the light chain variable region shown in SEQ ID NO:22.

[0029] To achieve the above objectives, according to a sixth aspect of the present invention, an antibody pair for detecting influenza A virus is provided, the antibody comprising a constant region, wherein the heavy chain constant region is selected from any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, IgD, or a combination of multiple constant regions; and the light chain constant region is selected from κ-type or λ-type light chain constant regions.

[0030] In an optional embodiment, the heavy chain constant region of the first antibody is SEQ ID NO:7 or a sequence having at least 80% identity with it, and the light chain constant region of the first antibody is SEQ ID NO:8 or a sequence having at least 80% identity with it.

[0031] In an optional embodiment, the heavy chain constant region of the second antibody is SEQ ID NO:19 or a sequence having at least 80% identity with it, and the light chain constant region of the second antibody is SEQ ID NO:8 or a sequence having at least 80% identity with it.

[0032] To achieve the above objectives, according to a seventh aspect of the present invention, a reagent for detecting influenza A virus is provided, the reagent comprising a first group of antibodies and a second group of antibodies, wherein the first group of antibodies comprises a first antibody in an antibody pair;

[0033] The second group of antibodies includes the second antibody in the antibody pair;

[0034] Optionally, one of the first group of antibodies and the second group of antibodies is a coating antibody, and the other is a labeled antibody;

[0035] The reagent includes the first antibody and the second antibody in the above antibody pair; the first antibody is a coating antibody and the second antibody is a labeled antibody, or the second antibody is a coating antibody and the first antibody is a labeled antibody;

[0036] In an optional embodiment, the coated antibody or labeled antibody is conjugated with biotin or a biotin derivative;

[0037] In one optional embodiment, the label conjugated to the labeled antibody is selected from colloidal gold, fluorescent microspheres, fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent labels, electrochemiluminescent labels, latex and nanoparticle labels;

[0038] In one optional embodiment, the coated antibody is coupled to a solid-phase support;

[0039] In one alternative embodiment, the solid support is selected from microspheres, plates, and membranes.

[0040] To achieve the above objectives, according to an eighth aspect of the present invention, a method for detecting influenza A virus is provided, comprising:

[0041] a) Under conditions sufficient to induce antibody / antigen binding, the aforementioned antibody pair or reagent is brought into contact with the sample to be tested to form an immune complex; and

[0042] b) Detect the presence of the immune complex, the presence of which indicates the presence of influenza A virus in the test sample.

[0043] To achieve the above objectives, according to a ninth aspect of the present invention, the use of the above-described antibody pairs or reagents in detecting influenza A virus or in preparing products for detecting influenza A virus is provided. Detailed Implementation

[0044] In a first aspect, embodiments of the present invention provide an antibody pair for detecting influenza A virus, the antibody pair comprising a first antibody, the first antibody comprising: three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3) in the heavy chain variable region shown in SEQ ID NO:9 and three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3) in the light chain variable region shown in SEQ ID NO:11; the antibody pair comprising a second antibody, the second antibody comprising: three heavy chain complementarity-determining regions (HCDR1, HCDR2, and HCDR3) in the heavy chain variable region shown in SEQ ID NO:20 and three light chain complementarity-determining regions (LCDR1, LCDR2, and LCDR3) in the light chain variable region shown in SEQ ID NO:22.

[0045] The complementary decision region is defined by any one or a combination of systems such as Kabat, Chothia, IMGT, AbM, or Contact.

[0046] In this invention, the term "antibody" is used in the broadest sense, and the antibody in the method of this invention can be a whole antibody, an antigen-binding fragment, or a polymeric antibody capable of binding to influenza A virus.

[0047] Whole antibodies can be monoclonal. Such whole antibodies are typically prepared by any suitable method known in the art. For example, antibody molecules are isolated from the serum of, for example, a mammal typically a rabbit or mouse, immunized with influenza A virus under suitable conditions. Monoclonal antibodies can be obtained by hybridoma or recombinant methods. The antigen-binding fragment includes an antigen-binding site, such as a Fab or F(ab)2 fragment. In an alternative embodiment, the antigen-binding fragment is selected from any one of the F(ab')2, Fab', Fab, Fv, and scFv of the antibody. The antigen-binding fragment of the above-described antibody typically has the same binding specificity as the antibody from which it originates. As will be readily understood by those skilled in the art according to the description of the present invention, the antigen-binding fragment of the above-described antibody can be obtained by, for example, enzymatic digestion (including pepsin or papain) and / or by chemical reduction of disulfide bonds. Based on the structure of the complete antibody disclosed in this invention, those skilled in the art can readily obtain the above-described antigen-binding fragment. The antigen-binding fragment of the above-described antibody can also be obtained by recombinant genetic techniques, also known to those skilled in the art, or by, for example, an automated peptide synthesizer, such as those sold by AppliedBioSystems. Polymerized antibodies are polymers formed by the polymerization of whole antibodies and antigen-binding fragments.

[0048] In a second aspect, embodiments of the present invention provide an antibody pair for detecting influenza A virus, the antibody pair comprising a first antibody and a second antibody; the first antibody having HCDR1 as shown in SEQ ID NO:1, HCDR2 as shown in SEQ ID NO:2, HCDR3 as shown in SEQ ID NO:3, LCDR1 as shown in SEQ ID NO:4, LCDR2 as shown in SEQ ID NO:5, and LCDR3 as shown in SEQ ID NO:6; the second antibody having HCDR1 as shown in SEQ ID NO:13, HCDR2 as shown in SEQ ID NO:14, HCDR3 as shown in SEQ ID NO:15, LCDR1 as shown in SEQ ID NO:16, LCDR2 as shown in SEQ ID NO:17, and LCDR3 as shown in SEQ ID NO:18.

[0049] In this invention, the terms "complementarity-determining region," "CDR," or "CDRs" refer to highly variable regions of the heavy and light chains of immunoglobulins, specifically regions containing one or more, or even all, of the major amino acid residues that contribute to the binding of an antibody or antigen-binding fragment to the antigen or epitope it recognizes. In specific embodiments of this invention, CDRs refer to highly variable regions of the heavy and light chains of the antibody.

[0050] The methods for defining CDRs are well known in the art and include: Kabat definition, Chothia definition, IMGT definition, Contact definition, and AbM definition. As described herein, "Kabat definition" refers to the definition system described in Kabat et al., USDept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" is found in Chothia et al., J Mol Biol 196:901-917 (1987). Other CDR definition methods may not strictly follow any of the above schemes but will still overlap with at least a portion of the CDR region defined by Kabat, although they may be shortened or lengthened based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below, with slight variations in labeling across different literature. Given the amino acid sequence of the variable region of an antibody, those skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods, not limited to those in Table 1, are also within the scope of this disclosure.

[0051] Table 1: CDR Definition 1

[0052]

[0053] 1. All CDRs defined in Table 1 are numbered according to the Kabat numbering system (see below), with amino acid numbers on the heavy chain represented by "H + number" and amino acid numbers on the light chain represented by "L + number". Those skilled in the art can readily map this Kabat numbering system to any variable region sequence without relying on any experimental data outside the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., USD ept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0054] 2As used in Table 1, “AbM” with a lowercase “b” refers to the CDR defined by the “AbM” antibody modeling software of Oxford Molecular.

[0055] 3 If neither H35A nor H35B exists, then CDR-H1 ends at bit 35; if only H35A exists, then CDR-H1 ends at bit 35A; if both H35A and H35B exist, then CDR-H1 ends at bit 35B.

[0056] 4 If neither H35A nor H35B exists, then CDR-H1 ends at bit 32; if only H35A exists, then CDR-H1 ends at bit 33; if both H35A and H35B exist, then CDR-H1 ends at bit 34.

[0057] 5 If neither H35A nor H35B exists, then CDR-H1 ends at bit 33; if only H35A exists, then CDR-H1 ends at bit 34; if both H35A and H35B exist, then CDR-H1 ends at bit 35.

[0058] According to embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one or a combination of systems such as Kabat, Chothia, IMGT, AbM or Contact.

[0059] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Kabat system.

[0060] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Chothia system.

[0061] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the IMGT system.

[0062] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the AbM system.

[0063] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Contact system.

[0064] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM, or Contact systems.

[0065] The antibody of the present invention also includes a frame region. In the present invention, the "frame region" or "FR" region includes a heavy chain frame region and a light chain frame region, which refers to the regions in the antibody heavy chain variable region and light chain variable region other than the CDR. The heavy chain frame region can be further subdivided into adjacent regions separated by the CDR, including HFR1, HFR2, HFR3 and HFR4 frame regions; the light chain frame region can be further subdivided into adjacent regions separated by the CDR, including LFR1, LFR2, LFR3 and LFR4 frame regions.

[0066] In this invention, the heavy chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0067] In some optional embodiments of the present invention, the antibody described in the present invention may also be an antibody having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the first antibody and the second antibody in the antibody pair in the FR region.

[0068] Thirdly, embodiments of the present invention provide an antibody pair for detecting influenza A virus.

[0069] The antibody pair comprises a first antibody having a heavy chain variable region shown in SEQ ID NO:9 and a light chain variable region shown in SEQ ID NO:11; the antibody pair comprises a second antibody having a heavy chain variable region shown in SEQ ID NO:20 and a light chain variable region shown in SEQ ID NO:22.

[0070] In an optional embodiment, the antibody pair comprises a first antibody having a heavy chain as shown in SEQ ID NO:10 and a light chain as shown in SEQ ID NO:12; and the antibody pair comprises a second antibody having a heavy chain as shown in SEQ ID NO:21 and a light chain as shown in SEQ ID NO:23.

[0071] Fourthly, embodiments of the present invention provide an antibody pair for detecting influenza A virus, the antibody pair comprising a first antibody, wherein the variable region of the heavy chain of the first antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:9, and the variable region of the light chain of the first antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:11; the antibody pair comprising a second antibody, wherein the variable region of the heavy chain of the second antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:20, and the variable region of the light chain of the second antibody is a conserved variant formed by the amino acid sequence mutation shown in SEQ ID NO:22.

[0072] The conserved variant refers to a mutant obtained by replacing the amino acid at the mutation site with an amino acid with the same chemical properties as the original amino acid.

[0073] The mutation includes the addition, deletion, substitution, or modification of one or more amino acids.

[0074] Fifthly, embodiments of the present invention provide an antibody pair for detecting influenza A virus, the antibody pair comprising a first antibody that binds to an epitope, the epitope being identical to the epitope bound by an antibody containing the heavy chain variable region shown in SEQ ID NO:9 and the light chain variable region shown in SEQ ID NO:11; the antibody pair comprising a second antibody that binds to an epitope: ....

[0075] The antibodies binding to the heavy chain variable region shown in SEQ ID NO:20 and the light chain variable region shown in SEQ ID NO:22 are the same epitopes.

[0076] The epitope, also known as an antigen epitope (AE), determines the ability of an antigen to specifically bind to an antibody. Antibodies bind to the same epitope because the amino acid fragments they bind to the target antigen are identical. Whether an antibody recognizes the same epitope as other antibodies can be confirmed by their competition for the epitope. Competition between antibodies can be evaluated using competitive binding assays, such as ELISA, fluorescence energy transfer assay (FRET), or fluorescence microassay (FMAT). The amount of antibody binding to the antigen is indirectly related to the binding ability of candidate competing antibodies (the antibody being tested) that compete for the same epitope. That is, the greater the binding amount or affinity of the antibody being tested for the same epitope, the lower the amount of antibody binding to the antigen, and the higher the amount of antibody binding to the antigen. Specifically, an appropriately labeled antibody and the antibody to be evaluated are added simultaneously to the antigen, and the binding of the antibody is detected using the labeling. By pre-labeling the antibody, the amount of antibody binding to the antigen can be easily determined. There are no particular limitations on the labeling; a labeling method appropriate to the assay technique is selected. Labeling methods include: fluorescent labeling, radioactive labeling, enzyme labeling, etc.

[0077] In an optional embodiment, the antibody further includes a constant region, wherein the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, or a combination of multiple constant regions; the light chain constant region is selected from the κ-type or λ-type light chain constant region. The λ-type light chain constant region may be selected from the λ1, λ2, λ3, and λ4 subtypes.

[0078] It should be noted that, in some embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the aforementioned constant region (SEQ ID NO: 7, 8, or 19).

[0079] In an optional implementation, the heavy chain constant region includes CH1 of IgG1, the hinge region of IgG1, CH2 of IgM, CH3 of IgM, and / or CH4 of IgM.

[0080] In one alternative embodiment, the antibody is a polymer formed by the polymerization of antibody monomers.

[0081] In some alternative implementations, the species source of the constant region is cattle, horses, pigs, sheep, goats, rats, mice, dogs, cats, rabbits, donkeys, deer, mink, chickens, ducks, geese, or humans.

[0082] Seventhly, embodiments of the present invention provide a reagent for detecting influenza A virus.

[0083] The reagent includes a first group of antibodies and a second group of antibodies, wherein the first group of antibodies includes the first antibody in the antibody pair described above.

[0084] The second group of antibodies includes the second antibody in the antibody pair described above.

[0085] In one optional implementation, one of the first group of antibodies and the second group of antibodies is a coating antibody, and the other is a labeled antibody.

[0086] It should be noted that the meaning of "reagent" in this application can be considered equivalent to the meaning of "kit".

[0087] In an optional embodiment, the coated antibody or labeled antibody is conjugated with biotin or a biotin derivative;

[0088] In one optional embodiment, the label conjugated to the labeled antibody is selected from colloidal gold, fluorescent microspheres, fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent labels, electrochemiluminescent labels, latex and nanoparticle labels;

[0089] In optional embodiments, the fluorescent dyes include, but are not limited to, fluorescein dyes and their derivatives (e.g., including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc., or their analogues), rhodamine dyes and their derivatives (e.g., including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc., or their analogues), and Cy series dyes and their derivatives (e.g., including but not limited to Cy2, Cy3, Cy3B, Cy3.5, C...). y5, Cy5.5, Cy3 and other similar substances), Alexa series dyes and their derivatives (including but not limited to Alexa Fluor 350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750 and other similar substances) and protein dyes and their derivatives (including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), polydiophytoxanthin-chlorophyll protein (preCP) and other similar substances).

[0090] In optional embodiments, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate dehydrogenase.

[0091] In optional embodiments, the radioactive isotopes include, but are not limited to, 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu, and 18F.

[0092] In optional embodiments, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, luciferin, fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridine ester and its derivatives, dioxane and its derivatives, rofenine and its derivatives, and peroxazone and its derivatives.

[0093] In optional embodiments, the nanoparticle-based markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0094] In optional embodiments, the colloid includes, but is not limited to, colloidal metals, dispersed dyes, dye-labeled microspheres, and latexes.

[0095] In optional embodiments, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0096] In an optional embodiment, the colloidal metal is colloidal gold.

[0097] In one optional embodiment, the coated antibody is coupled to a solid-phase support;

[0098] In one alternative embodiment, the solid support is selected from microspheres, plates, and membranes.

[0099] Eighthly, embodiments of the present invention provide a method for detecting influenza A virus, comprising:

[0100] a) Under conditions sufficient to induce antibody / antigen binding, the aforementioned antibody pair or reagent is brought into contact with the sample to be tested to form an immune complex; and

[0101] b) Detect the presence of the immune complex, the presence of which indicates the presence of influenza A virus in the test sample.

[0102] To achieve the above objectives, according to a ninth aspect of the present invention, the use of the above-described antibody pairs or reagents in detecting influenza A virus or in preparing products for detecting influenza A virus is provided.

[0103] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0104] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. While any methods and materials similar to or equivalent to those described herein may be used in the practice or testing of formulations or unit doses herein, some methods and materials are described hereby. Unless otherwise stated, the techniques employed or considered herein are standard methods. Materials, methods, and examples are illustrative and not limiting in nature.

[0105] Unless otherwise specified, the practice of this invention will employ conventional techniques of cell biology, molecular biology (including recombinant technologies), microbiology, biochemistry, and immunology, which are within the capabilities of those skilled in the art. This technique is well explained in the literature, such as *Molecular Cloning: A Laboratory Manual*, 2nd edition (Sambrook et al., 1989); *Oligonucleotide Synthesis* (edited by M.J. Gait, 1984); *Animal Cell Culture* (edited by R.R. Freshney, 1987); *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental Immunology* (edited by D.M. Weir and C.C. Blackwell); *Gene Transfer Vectors for Mammalian Cells* (edited by J.M. Miller and M.P. Calos, 1987); *Current Protocols in Molecular Biology* (edited by F.M. Mausubel et al., 1987); and *PCR: The Polymerase Chain Reaction*. The references cited in the references are: "Reaction" (Mullis et al., ed., 1994); and "Current Protocols in Immunology" (JEColigan et al., ed., 1991), each of which is explicitly incorporated herein by reference.

[0106] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0107] Based on long-term, creative research on influenza A virus, the applicant discovered two antibodies that meet the requirements for influenza A virus detection.

[0108] Example 1 Antibody Preparation

[0109] In this embodiment, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. The MagExtractor RNA extraction kit was purchased from TOYOBO. BD SMART TMThe RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen Biotech. Primer synthesis and gene sequencing were performed by Invitrogen. The hybridoma cell line secreting monoclonal antibodies against influenza A virus was an existing hybridoma cell line, which was revived and ready for use.

[0110] (1) Antibody gene preparation

[0111] mRNA was extracted from hybridoma cell lines that secrete monoclonal antibodies against influenza A virus, and DNA products were obtained by RT-PCR. The product was then inserted into the pMD-18T vector after being subjected to an A-addition reaction with rTaq DNA polymerase. The vector was then transformed into DH5α competent cells. After bacterial growth, four clones of the Heavy Chain and Light Chain genes were collected and sent to a gene sequencing company for sequencing.

[0112] (2) Sequence analysis of the variable region gene of influenza A virus antibody

[0113] The gene sequences obtained from the sequencing were analyzed in the Kabat antibody database and VNTI11.5 software was used to confirm that the genes amplified by both heavy and light chain primer pairs were correct. Among the gene fragments amplified by the Light Chain primer pair, the VL gene sequence was approximately 320 bp, with a 57 bp leader peptide sequence preceding it. Among the gene fragments amplified by the Heavy Chain primer pair, the VH gene sequence was approximately 360 bp, belonging to the VH1 gene family, with a 57 bp leader peptide sequence preceding it.

[0114] (3) Construction of recombinant antibody expression plasmid

[0115] pcDNA TM 3.4 The vector is a constructed recombinant antibody eukaryotic expression vector. This expression vector has been introduced with multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector. Based on the sequencing results of the variable region gene of the antibody in pMD-18T, VL and VH gene-specific primers of this antibody were designed, with HindIII and EcoRI restriction sites and protective bases at both ends, respectively. The LightChain gene fragment and Heavy Chain gene fragment were amplified by PCR.

[0116] The Heavy Chain and Light Chain gene fragments were digested with HindIII / EcoRI, and the 3.4A vector was also digested with HindIII / EcoRI. After purification and recovery of the fragments and vector, the Heavy Chain gene and Light Chain gene were ligated into the 3.4A expression vector to obtain recombinant expression plasmids of Heavy Chain and Light Chain, respectively.

[0117] 2. Recombinant antibody production

[0118] HEK293 cells were prematurely revived and passaged to a 200ml volume to achieve a cell density of 3–5 × 10⁻⁶ cells / mL. 6 Cell density reached the required antibody concentration and cell viability >95%; cells were washed by centrifugation, reconstituted with culture medium, and the cell density was adjusted to 2.9 × 10⁻⁶ cells / ml. 6 Cells were washed at a concentration of cells / ml and reconstituted with culture medium, which served as a cell dilution buffer. Plasmid DNA and transfection reagent dilution buffers were prepared separately using culture medium. The transfection reagent dilution buffer was added to the plasmid DNA dilution buffer, mixed well, and incubated at room temperature for 15 min. This mixture was then slowly added to the cell dilution buffer over 1 min, mixed well, and samples were taken for cell counting. Cell viability after transfection was recorded and observed. The cells were then incubated at 35°C with a rotation speed of 120 rpm and a CO2 concentration of 8%. After 13 days, the samples were centrifuged and collected. The supernatant was purified using a protein A affinity chromatography column. 6 μg of the purified antibody was subjected to reducing SDS-PAGE. The reducing SDS-PAGE showed two bands: one with a Mr of 50 kDa (heavy chain) and the other with a Mr of 28 kDa (light chain).

[0119] The resulting antibodies were named Anti-Flua-012 and Anti-Flua-013. The heavy chain (H) and light chain (L) sequences of the above antibodies are shown in the table below:

[0120] Table 2 Antibody Sequences

[0121] Antibody name Heavy chain Light chain Anti-Flua-012 SEQ ID NO:10 SEQ ID NO:12 Anti-Flua-013 SEQ ID NO:21 SEQ ID NO:23

[0122] Example 2: Preparation of Detection Reagents

[0123] The Anti-Flua-012 antibody was used as the labeling antibody, and the Anti-Flua-013 antibody was used as the coating antibody. The experimental procedure is as follows:

[0124] (1) Wrapping:

[0125] Dilute the secondary antibodies used to coat the T line and C line with coating diluent to 1 mg / ml. Use a gold sputtering membrane spectrometer to draw detection lines evenly on the NC membrane (T line and C line, 1.0 μl / cm for each line), being careful not to scratch the membrane. Then place the membrane in a 50°C oven for drying for more than 4 hours before use.

[0126] (2) Mark:

[0127] Add 1 ml of 40,000 AU to a certain amount of 0.2 mol / L K₂CO₃, shake well for 1 min, then add 10 μg of the antibody to be labeled, shake well for 1 min, and finally add the blocking agent, shake well for 1 min. Centrifuge at 10,000 rpm for 7 min using a Xiangyi benchtop centrifuge, collect the precipitate, and concentrate the precipitate to 1 / 10 of the labeled volume. The centrifugation speed can be adjusted appropriately according to the centrifugation effect. The supernatant should be light pink or colorless after centrifugation, with no non-reconstituteable precipitate.

[0128] (3) Spraying with gold: The complex of the antibody and colloidal gold labeled in (2) is diluted to the specified concentration and then sprayed with gold, and dried for at least 2 hours.

[0129] (4) Sample pad preparation: Spread 2.4 ml of the prepared sample pad treatment solution onto glass fibers that are 1.7 cm wide and 30 cm long, and dry at 50°C for more than 2 hours.

[0130] (5) Assembly: Assemble the sample pad, base plate, absorbent paper, conjugate pad, coating membrane, etc., and cut them into 3.0mm pieces to make the corresponding immunoassay strips.

[0131] Example 3 Reagent Performance Evaluation

[0132] (1) Dilute the sample containing influenza A virus with sample diluent;

[0133] (2) Use a pipette to transfer 50 μL of the diluted sample and add it onto the prepared immunoassay strip for chromatography;

[0134] (3) Read the results visually after 15-20 minutes, and record the T-line color development based on the reading on the test reagent card.

[0135] The results of testing different influenza A virus strains (National Institute for Biological Standards and Control) are shown in the table below:

[0136]

[0137]

[0138]

[0139] It should be noted that:

[0140] 1. The colloidal gold card has 10 readings: 1, 2, 3, 4, 5, 6, 7, 8, 9, and B. The corresponding T-line colors of these 10 readings decrease in color from left to right. 1 indicates the darkest T-line color, 9 indicates the lightest T-line color, B indicates no color development, and B+ indicates almost no color development. In the table, "8+" means a color slightly darker than 8 but not reaching 7, and so on for the others marked with "+". In the table, "8-" means a color slightly lighter than 8 but not reaching 9, and so on for the others marked with "-".

[0141] Example 4 Reagent Cross-Reactivity Assessment

[0142] The cross-reactivity of the test kit was assessed using other respiratory pathogens other than influenza A virus, clinical nasopharyngeal swab negative results, and recombinant influenza B virus antigen.

[0143] (1) Use a pipette to transfer 50 μL of the diluted sample and add it onto the prepared immunoassay strip for chromatography;

[0144] (2) Read the results visually after 15-20 minutes, and record the T-line color development based on the reading on the test reagent card.

[0145]

[0146]

[0147] Note: PK2-FBN1 is a recombinant influenza B virus antigen.

[0148] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

[0149] The partial amino acid sequence involved in this application is shown below:

[0150]

[0151]

Claims

1. An antibody pair for detecting influenza A virus, characterized in that, The antibody pair includes a first antibody, the complementarity-determining regions of which are: three heavy chain complementarity-determining regions HCDR1, HCDR2, and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:9, and three light chain complementarity-determining regions LCDR1, LCDR2, and LCDR3 in the light chain variable region as shown in SEQ ID NO:11; and The antibody pair includes a second antibody, the complementarity-determining regions of which are: three heavy chain complementarity-determining regions HCDR1, HCDR2 and HCDR3 in the heavy chain variable region as shown in SEQ ID NO:20, and three light chain complementarity-determining regions LCDR1, LCDR2 and LCDR3 in the light chain variable region as shown in SEQ ID NO:

22. The complementary decision region is defined by any one of the systems Kabat, Chothia, IMGT, AbM, or Contact.

2. An antibody pair for detecting influenza A virus, characterized in that, The antibody pair includes a first antibody, the amino acid sequences of which are HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, as shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:4, respectively. As shown in SEQ ID NO:5 and SEQ ID NO:6; and The antibody pair includes a second antibody, the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the second antibody being shown in SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, and SEQ ID NO:18, respectively.

3. An antibody pair for detecting influenza A virus, characterized in that, The antibody pair comprises a first antibody, which comprises at least one of (1)-(2): (1) The heavy chain variable region with an amino acid sequence as shown in SEQ ID NO:9 and the light chain variable region with an amino acid sequence as shown in SEQ ID NO:11; (2) The heavy chain with the amino acid sequence shown in SEQ ID NO:10 and the light chain with the amino acid sequence shown in SEQ ID NO:12; and The antibody pair comprises a second antibody, the second antibody comprising at least one of (a)-(b): (a) The heavy chain variable region with amino acid sequences as shown in SEQ ID NO:20 and the light chain variable region with amino acid sequences as shown in SEQ ID NO:22; (b) The heavy chain with the amino acid sequence shown in SEQ ID NO:21 and the light chain with the amino acid sequence shown in SEQ ID NO:

23.

4. The antibody pair according to claim 2, characterized in that, The antibody pair comprises a first antibody, the first antibody heavy chain variable region is shown in SEQ ID NO:9, the first antibody light chain variable region is shown in SEQ ID NO:11, the frame region of the conserved variant formed by the mutation of the first antibody has at least 80% identity with the frame region of the first antibody before the mutation, and the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the first antibody are shown in SEQ ID NO:1~6 in sequence; The antibody pair comprises a second antibody, the variable region of the heavy chain of the second antibody is shown in SEQ ID NO:20, the variable region of the light chain of the second antibody is shown in SEQ ID NO:22, the frame region of the conserved variant formed by the mutation of the second antibody has at least 80% identity with the frame region of the second antibody before the mutation, and the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of the second antibody are shown in SEQ ID NO:13~18 in sequence.

5. The antibody pair according to any one of claims 1-4, characterized in that, The antibody further includes a constant region; wherein the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, or a combination of multiple constant regions; the light chain constant region is selected from the κ-type or λ-type light chain constant region.

6. The antibody pair according to claim 5, characterized in that, The heavy chain constant region of the first antibody is a sequence with at least 80% identity to SEQ ID NO:7, and the light chain constant region of the first antibody is a sequence with at least 80% identity to SEQ ID NO:8; The heavy chain constant region of the second antibody is a sequence with at least 80% identity to SEQ ID NO:19, and the light chain constant region of the second antibody is a sequence with at least 80% identity to SEQ ID NO:

8.

7. The antibody pair according to claim 6, characterized in that, The amino acid sequence of the heavy chain constant region of the first antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain constant region of the first antibody is shown in SEQ ID NO:

8. The amino acid sequence of the heavy chain constant region of the second antibody is shown in SEQ ID NO:19, and the amino acid sequence of the light chain constant region of the second antibody is shown in SEQ ID NO:

8.

8. A reagent for detecting influenza A virus, characterized in that, The reagent includes a first group of antibodies and a second group of antibodies, wherein the first group of antibodies includes the first antibody as described in any one of claims 1-7; The second group of antibodies includes the second antibody as described in any one of claims 1-7.

9. The reagent according to claim 8, characterized in that, One of the first group of antibodies and the second group of antibodies is a coating antibody, and the other group is a labeled antibody.

10. The reagent according to claim 9, characterized in that, The coated antibody or labeled antibody is conjugated with biotin.

11. The reagent according to claim 9, characterized in that, The labeled antibody-conjugated markers are selected from colloidal gold, fluorescent microspheres, fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent markers, electrochemiluminescent markers, latex and nanoparticle markers.

12. The reagent according to claim 9, characterized in that, The coated antibody is coupled to a solid-phase carrier.

13. The reagent according to claim 12, characterized in that, The solid support is selected from microspheres, plates, and membranes.

14. Use of the antibody pair according to any one of claims 1-7 or the reagent according to claim 8 in the preparation of products for detecting influenza A virus.

Citation Information

Patent Citations

  • Anti-influenza A virus antibody, detection kit and preparation method

    CN114181304A